AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03483246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum.
Study NCT03483246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham-transplantation Placebo
Description: The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum.
Study NCT04288726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD30.CAR-EBVST cells
Description: The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach an MTD. This will be administered as a single infusion of the full dose for each level, which was already shown to be safe in the first 3 patients treated at dose level 3. Since we have not observed any dose limiting toxicities at the current dose level (Dose Level 3 as of June 2022), we propose to include a new higher dose level (8 × 10\^8).There will be a gap of 4 weeks between the first and second patient, and between the second and the third patient, on each dose level.
Study NCT04296383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus Xiyanping injection
Description: Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d;Xiyanping injection intravenously, 0.4mL / (kg.d) daily, Qd
Study NCT04296383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d
Study NCT04063566 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Prostate cancer screening MRI
Study NCT04063566 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostate-specific antigen (PSA) test
Description: Blood test for PSA levels
Study NCT01534975 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: contrast agent
Description: we are randomizing patients to different contrast agents.
Study NCT04800445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary CRP
Description: Salivary C reactive protein in neonatal sepsis
Study NCT01548950 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil singly or in association with Bosentan
Description: Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
Study NCT01504828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
Study NCT00468923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan/HCT
Description: Candesartan 16 mg/HCT 12.5 once daily
Study NCT00468923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 10 mg once daily
Study NCT02351128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Study NCT00270699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN4delta30-200,201
Description: Live attenuated dengue 4 vaccine (one of three doses)
Study NCT03916237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular School Based Health Asthma Care
Description: Regular care in the School Health Program
Study NCT00270699 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN4delta30-200,201
Study NCT04639687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food as Medicine Delivery
Description: 12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video
Study NCT04639687 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Food as Medicine Delivery
Description: 12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video
Study NCT04592991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i
Description: Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.
Study NCT04592991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i
Description: Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.
Study NCT03564899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lighter intensity physical activity intervention
Description: Prescription of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve
Study NCT03564899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Higher intensity physical activity intervention
Description: Prescription of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve
Study NCT01033864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: 1 g per day b.i.d. p.o. for at least 1 month
Study NCT01033864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-MPS
Description: 720 mg b.i.d. p.o. for at least 1 month
Study NCT01033864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg per day p.o.
Study NCT01033864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg per day p.o.
Study NCT01862328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle
Study NCT01862328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV) in a 21-day cycle:~* Paclitaxel on Day 1 of each cycle
Study NCT01862328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle
Study NCT01862328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (IV) in participants in a 21-day cycle:~- Docetaxel on Day 1 of each cycle
Study NCT01862328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (IV) in participants in a 21-day cycle:~- Carboplatin on Day 1 of each cycle
Study NCT02889328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 100mg continuous dosing arm
Study NCT00219557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
Study NCT00219557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
Study NCT00219557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
Study NCT01218620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study NCT01218620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Given PO
Study NCT02408835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO™
Description: Negative pressure wound therapy device for closed surgical wounds.
Study NCT03549078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity.
Study NCT01801865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE OPTIMA MR430s with HDX/GE Electronics
Study NCT03068234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.
Study NCT03068234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.
Study NCT03068234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo for pirfenidone capsule
Study NCT03068234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroids
Description: Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
Study NCT03068234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
Study NCT04524793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
Study NCT04524793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical examinations
Description: GSV/SSV/AASV reflux, CEAP Classification (Clinical, Aetiological, Anatomical and Pathophysiology), Venous Clinical Severity Score (VCSS) and duplex ultrasound
Study NCT02323373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid - topical
Description: Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.
Study NCT02323373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of saline solution administered with anesthesia during 10 minutes
Study NCT02323373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid - intravenous
Description: Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.
Study NCT01450306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg d-cycloserine, oral, 1 dose
Study NCT01450306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Single session graded in vivo exposure therapy, 60-180 minutes
Study NCT01450306 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exposure therapy
Description: Single session graded in vivo exposure therapy, 60-180 minutes
Study NCT01450306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
Study NCT01492907 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MeIQx
Description: On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
Study NCT01492907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatectomy
Description: Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
Study NCT03886610 — intervention group
Intervention type: OTHER
Intervention: Healthy controls
Description: individuals without spinal cord injury
Study NCT03886610 — intervention group
Intervention type: OTHER
Intervention: Subacute SCI patients
Description: individuals with spinal cord injury ≥ 2 weeks
Study NCT03886610 — intervention group
Intervention type: OTHER
Intervention: Chronic SCI patients
Description: individuals with spinal cord injury ≥ 24 months
Study NCT04261829 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous Fat Transfer
Description: Female breast cancer patients who were surgically treated with mastectomy could opt for a full breast reconstruction with Autologous Fat Transfer in combination with external expansion.
Study NCT00597610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound 3-D (TRUS)
Description: Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
Study NCT03268980 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Hospital Staff group
Description: One-page questionnaire with 15 questions about tobacco habits
Study NCT03268980 — intervention group
Intervention type: OTHER
Intervention: Questionnaire students and patients group
Description: One-page questionnaire with 17 questions about tobacco habits
Study NCT02921685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Four dose levels will be tested.
Study NCT02852174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Description: Mindfulness meditation training
Study NCT02375971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Administered as an intravitreal injection
Study NCT02375971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
Study NCT00774501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: image guidance with general anesthesia and suspended ventilation during treatment delivery
Description: All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.~Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.~The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery.
Study NCT03244761 — intervention group
Intervention type: PROCEDURE
Intervention: The modified HFT
Description: The HFT was modified by increasing the expiratory resistance.
Study NCT03266861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise oximetry
Description: Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
Study NCT04565197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: convalescent plasma
Description: Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~* Transfuse first aliquot for 2-3 hours (\~1.4 to 2 mL/min)~* Transfuse second aliquot at same rate 2 hours after completion of first aliquot
Study NCT02174510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg lurasidone
Description: single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
Study NCT02174510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg lurasidone
Description: single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
Study NCT02174510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg lurasidone
Description: single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
Study NCT02174510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT03948529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: eltrombopag at the starting dose of 50mg/day. After 2 weeks of eltrombopag initiation and in the absence of platelet response, eltrombopag will be increased every two weeks (50mg increase) up to a maximum dose of 150mg/day (2 maximum escalation from D1, with maximum dose escalation phase of 4 weeks).
Study NCT02598232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1,414nm Nd:YAG Laser System
Description: It has high absorption coefficient in water and a short pulse width.
Study NCT00907543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative treatment of chemotherapy and radiation
Description: Cisplatin + 5FU with concurrent radiation followed by surgery
Study NCT00907543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative treatment of chemotherapy and radiation
Description: Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation
Study NCT00449865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: creatine
Description: Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo.
Study NCT00449865 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT01622218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Clown
Description: Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
Study NCT06280911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Date Fruit group
Description: Consumption of Date Fruit
Study NCT06280911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nipple group
Description: Nipple Stimulation
Study NCT01218620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Given PO
Study NCT01218620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: Given IV
Study NCT01481948 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food, Fun, & Fitness Internet Program for Girls
Description: This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.